{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:25:43Z","timestamp":1794500743285,"version":"4.9.1"},"reference-count":74,"publisher":"European Respiratory Society (ERS)","issue":"165","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2022,5,3]]},"published-print":{"date-parts":[[2022,9,30]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p><jats:italic>Aspergillus fumigatus<\/jats:italic>is a common saprophytic fungus causing allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis (CF). The recommended first-line treatment for ABPA is oral steroids, followed by antifungal therapy. However, both treatments are not free from adverse effects; thus, efforts are being made to identify new drugs showing the same effectiveness but with fewer or no side-effects. Therein, biologic drugs have been significantly implemented in clinical practice in treating ABPA in patients with CF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To systematically review the available literature, providing evidence for the administration of biologic drugs as a new potential treatment of ABPA in both the paediatric and adult populations with CF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic review of the literature published between January 2007 and July 2021 was performed, using a protocol registered with the International Prospective Register of Systematic Reviews (PROSPERO CRD42021270932).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 21 studies focusing on the use of biologics in treating ABPA in CF patients was included. We highlighted a paucity of data providing evidence for biologic drug use in ABPA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Scientific evidence is insufficient to support firm conclusions and randomised clinical trials are urgently required to investigate the efficacy and safety of biologics for ABPA in CF patients.<\/jats:p><\/jats:sec>","DOI":"10.1183\/16000617.0011-2022","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T05:50:33Z","timestamp":1658987433000},"page":"220011","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Biologic drugs in treating allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: a systematic review"],"prefix":"10.1183","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-3083","authenticated-orcid":false,"given":"Sara","family":"Manti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-5800","authenticated-orcid":false,"given":"Alessandro","family":"Giallongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4291-0195","authenticated-orcid":false,"given":"Giuseppe Fabio","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Papale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enza","family":"Mul\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Aloisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novella","family":"Rotolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"2024102404045689000_31.165.220011.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2009.11.010"},{"key":"2024102404045689000_31.165.220011.2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00576-6"},{"key":"2024102404045689000_31.165.220011.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.02.003"},{"key":"2024102404045689000_31.165.220011.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2014.03.001"},{"key":"2024102404045689000_31.165.220011.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.04.007"},{"key":"2024102404045689000_31.165.220011.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2018.06.029"},{"key":"2024102404045689000_31.165.220011.7","doi-asserted-by":"publisher","DOI":"10.1086\/376525"},{"key":"2024102404045689000_31.165.220011.8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/pai.13619","article-title":"Type 2 inflammation in cystic fibrosis: new insights","volume":"33","author":"Manti","year":"2022","journal-title":"Pediatric Allergy Immunol"},{"key":"2024102404045689000_31.165.220011.9","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12141"},{"key":"2024102404045689000_31.165.220011.10","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2016.1249853"},{"key":"2024102404045689000_31.165.220011.11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-86-4-405"},{"key":"2024102404045689000_31.165.220011.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200805-737OC"},{"key":"2024102404045689000_31.165.220011.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01816-2015"},{"key":"2024102404045689000_31.165.220011.14","first-page":"CD002204","article-title":"Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","volume":"11","author":"Elphick","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102404045689000_31.165.220011.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1503104"},{"key":"2024102404045689000_31.165.220011.16","doi-asserted-by":"crossref","first-page":"212590","DOI":"10.7573\/dic.212590","article-title":"Novel therapeutic targets for allergic airway disease in children","volume":"8","author":"Giallongo","year":"2019","journal-title":"Drugs Context"},{"key":"2024102404045689000_31.165.220011.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"2024102404045689000_31.165.220011.18","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102404045689000_31.165.220011.19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ppul.23612","article-title":"Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients","volume":"52","author":"Nov\u00e9-Josserand","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2024102404045689000_31.165.220011.20","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.035519"},{"key":"2024102404045689000_31.165.220011.21","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20804"},{"key":"2024102404045689000_31.165.220011.22","doi-asserted-by":"publisher","DOI":"10.1080\/02770900902849871"},{"key":"2024102404045689000_31.165.220011.23","first-page":"88","article-title":"Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin E therapy (omalizumab)","volume":"17","author":"Elmallah","year":"2012","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2024102404045689000_31.165.220011.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2012.11.004"},{"key":"2024102404045689000_31.165.220011.25","doi-asserted-by":"publisher","DOI":"10.1177\/1753465814547517"},{"key":"2024102404045689000_31.165.220011.26","first-page":"1839","article-title":"Anti IgE antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis","volume":"18","author":"Zicari","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2024102404045689000_31.165.220011.27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.medcli.2014.05.020","article-title":"Papel de omalizumab en el tratamiento de la aspergilosis broncopulmonar al\u00e9rgica en pacientes con fibrosis qu\u00edstica","volume":"144","author":"Delgado Pecell\u00edn","year":"2015","journal-title":"Med Clin (Barc)"},{"key":"2024102404045689000_31.165.220011.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.11.007"},{"key":"2024102404045689000_31.165.220011.29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/JAA.S156049","article-title":"Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"11","author":"Ashkenazi","year":"2018","journal-title":"J Asthma Allergy"},{"key":"2024102404045689000_31.165.220011.30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2019.07.011","article-title":"Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis","volume":"19","author":"Koutsokera","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024102404045689000_31.165.220011.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02147.x"},{"key":"2024102404045689000_31.165.220011.32","unstructured":"ClinicalTrials.gov . An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients with Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00787917. Date last accessed: 25 August 2021. Date last updated: 26 September 2011."},{"key":"2024102404045689000_31.165.220011.33","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015624204"},{"key":"2024102404045689000_31.165.220011.34","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21002"},{"key":"2024102404045689000_31.165.220011.35","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jaip.2019.01.056","article-title":"Successful treatment with omalizumab of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: case reports and literature review","volume":"7","author":"Parisi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102404045689000_31.165.220011.36","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22937"},{"key":"2024102404045689000_31.165.220011.37","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20907"},{"key":"2024102404045689000_31.165.220011.38","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.2009.09k005"},{"key":"2024102404045689000_31.165.220011.39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13223-019-0397-3","article-title":"Use of mepolizumab in adult patients with cystic fibrosis and an eosinophilic phenotype: case series","volume":"16","author":"Zhang","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2024102404045689000_31.165.220011.40","doi-asserted-by":"crossref","first-page":"e00696","DOI":"10.1002\/rcr2.696","article-title":"Mepolizumab use in cystic fibrosis-associated allergic bronchopulmonary aspergillosis","volume":"9","author":"Boyle","year":"2020","journal-title":"Respirol Case Rep"},{"key":"2024102404045689000_31.165.220011.41","first-page":"CD010288","article-title":"Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","volume":"3","author":"Jat","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102404045689000_31.165.220011.42","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12595"},{"key":"2024102404045689000_31.165.220011.43","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxp102"},{"key":"2024102404045689000_31.165.220011.44","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2147\/DDDT.S243053","article-title":"Dupilumab: clinical efficacy of blocking IL-4\/IL-13 signalling in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Kariyawasam","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"2024102404045689000_31.165.220011.45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13223-020-00454-w","article-title":"Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?","volume":"16","author":"M\u00fcmmler","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2024102404045689000_31.165.220011.46","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaip.2019.11.031","article-title":"Dupilumab treatment for allergic bronchopulmonary aspergillosis: a case series","volume":"8","author":"Ramonell","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102404045689000_31.165.220011.47","doi-asserted-by":"crossref","first-page":"omaa029","DOI":"10.1093\/omcr\/omaa029","article-title":"Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis","volume":"2021","author":"Ali","year":"2021","journal-title":"Oxf Med Case Reports"},{"key":"2024102404045689000_31.165.220011.48","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2169\/internalmedicine.6679-20","article-title":"Successful treatment of mepolizumab- and prednisolone-resistant allergic bronchopulmonary aspergillosis with dupilumab","volume":"60","author":"Mikura","year":"2021","journal-title":"Intern Med"},{"key":"2024102404045689000_31.165.220011.49","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.12998\/wjcc.v9.i23.6922","article-title":"Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: a case report","volume":"9","author":"Nishimura","year":"2021","journal-title":"World J Clin Cases"},{"key":"2024102404045689000_31.165.220011.50","doi-asserted-by":"crossref","first-page":"1753466620961648","DOI":"10.1177\/1753466620961648","article-title":"Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review","volume":"14","author":"Eraso","year":"2020","journal-title":"Ther Adv Respir Dis"},{"issue":"Suppl. 26","key":"2024102404045689000_31.165.220011.51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/pai.13357","article-title":"Allergic bronchopulmonary aspergillosis in children","volume":"31","author":"Manti","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"2024102404045689000_31.165.220011.52","doi-asserted-by":"crossref","first-page":"582964","DOI":"10.3389\/fped.2020.582964","article-title":"Current approach in the diagnosis and management of allergic bronchopulmonary aspergillosis in children with cystic fibrosis","volume":"8","author":"Sunman","year":"2020","journal-title":"Front Pediatr"},{"key":"2024102404045689000_31.165.220011.53","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1295716"},{"key":"2024102404045689000_31.165.220011.54","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.2002.00738.x"},{"key":"2024102404045689000_31.165.220011.55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/jof6020067","article-title":"High-frequency direct detection of triazole resistance in Aspergillus fumigatus from patients with chronic pulmonary fungal diseases in India","volume":"6","author":"Singh","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2024102404045689000_31.165.220011.56","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/MCP.0000000000000625","article-title":"Prevention of drug-related complications in cystic fibrosis","volume":"25","author":"van der Meer","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"2024102404045689000_31.165.220011.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2005.05.019"},{"key":"2024102404045689000_31.165.220011.58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/mmy\/myz015","article-title":"Posaconazole therapy in children with cystic fibrosis and Aspergillus-related lung disease","volume":"58","author":"Patel","year":"2020","journal-title":"Med Mycol"},{"key":"2024102404045689000_31.165.220011.59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/jof2020017","article-title":"Allergic bronchopulmonary aspergillosis","volume":"2","author":"Tracy","year":"2016","journal-title":"J Fungi (Basel)"},{"key":"2024102404045689000_31.165.220011.60","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2010-0224OC"},{"key":"2024102404045689000_31.165.220011.61","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700379"},{"key":"2024102404045689000_31.165.220011.62","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3390\/pathogens10050618","article-title":"Fungal infection and inflammation in cystic fibrosis","volume":"10","author":"Poore","year":"2021","journal-title":"Pathogens"},{"key":"2024102404045689000_31.165.220011.63","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/antibiotics10040357","article-title":"Allergic diseases caused by Aspergillus species in patients with cystic fibrosis","volume":"10","author":"Curran","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2024102404045689000_31.165.220011.64","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI Biologicals Guidelines \u2013 recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"2024102404045689000_31.165.220011.65","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.anai.2018.02.029","article-title":"Uses of biologics in allergic diseases: what to choose and when","volume":"120","author":"Saco","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024102404045689000_31.165.220011.66","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2024102404045689000_31.165.220011.67","doi-asserted-by":"publisher","DOI":"10.4137\/CCRPM.S7793"},{"key":"2024102404045689000_31.165.220011.68","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03214.x"},{"key":"2024102404045689000_31.165.220011.69","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2017.03.002","article-title":"Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience","volume":"139","author":"Chipps","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2024102404045689000_31.165.220011.70","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1080\/02770903.2020.1789875","article-title":"Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis","volume":"58","author":"Fu","year":"2021","journal-title":"J Asthma"},{"key":"2024102404045689000_31.165.220011.71","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1513\/AnnalsATS.201902-122OC","article-title":"Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. A cohort study using national registry data","volume":"16","author":"Frost","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2024102404045689000_31.165.220011.72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2024102404045689000_31.165.220011.73","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fcimb.2020.00372","article-title":"CFTR modulators dampen Aspergillus-induced reactive oxygen species production by cystic fibrosis phagocytes","volume":"10","author":"Currie","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"2024102404045689000_31.165.220011.74","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00758-2020"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0011-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:05:12Z","timestamp":1740373512000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0011-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":74,"journal-issue":{"issue":"165","published-online":{"date-parts":[[2022,7,27]]},"published-print":{"date-parts":[[2022,9,30]]}},"alternative-id":["10.1183\/16000617.0011-2022"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0011-2022","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1183\/16000617.0011-2022.supp1","asserted-by":"subject"}]},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]}}}